Orexigen soars on CV data that FDA didn't want released

Orexigen Therapeutics soared 32% to close at $7.64 per share on 3 March after the San Diego-based company disclosed a newly issued patent for its weight loss drug Contrave (naltrexone and bupropion) that contained positive interim results from a cardiovascular outcomes trial (CVOT) known as the Light study – data that the US FDA expressly asked Orexigen not to disclose.